Recludix Pharma, Sanofi Enter into Collaboration on Oral STAT6 Inhibitor

Image Credit: Adobe Stock Images/Lars Neumann

Recludix Pharma, a pharmaceutical technology company, has announced a partnership with Sanofi to commercialize oral small molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for patients with immunological and inflammatory (I&I) diseases. Per terms of the deal, Recludix will receive $125 million in near-term payments. Upon completion of development, regulatory, and sales milestones, the pharma organization may receive up to an additional $1.2 billion.

Until the start of phase 2 clinical trials, Recludix will advance STAT6 inhibitors from preclinical research and development. From there, Sanofi will assume all responsibilities and obtain global rights to small molecule STAT6 inhibitors.

"Recludix’s approach to targeting STAT6 has significant potential for a number of I&I diseases, especially where a precisely tailored oral therapy could best fit within the patient’s needs at various stages of disease," said Frank Nestle, global head of research, chief security officer, Sanofi, in a press release. "We are excited to partner with the Recludix team to continue to advance innovative strategies for targeting this previously considered undruggable target, aligned with our mission to best serve patients with inflammatory disease."

Reference: Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications. GlobeNewswire. July 20, 2023. Accessed July 24, 2023. https://www.globenewswire.com/news-release/2023/07/20/2708122/0/en/Recludix-Pharma-Enters-into-a-Strategic-Collaboration-with-Sanofi-to-Advance-Novel-Oral-STAT6-Inhibitor-in-Multiple-Immunological-and-Inflammatory-Indications.html